CNS Pharmaceuticals, Inc. Development Costs, Period Cost
CNS Pharmaceuticals, Inc. (CNSP) reported Development Costs, Period Cost of $1.00 million for the 1-month period ending 2020-04-30, per its 10-Q filed 2023-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DevelopmentCosts · last filed 2023-08-14
- 2020-04-30: Development Costs, Period Cost 1 month $1.00M; Development Costs, Period Cost 1 month as first filed $225.00K.
| Period end | Development Costs, Period Cost 1 month | Development Costs, Period Cost 1 month as first filed |
|---|---|---|
| 2020-04-30 | $1.00M 10-Q · filed 2023-08-14 | $225.00K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |